carbamates has been researched along with Recrudescence in 68 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatitis C virus could be eliminated in all patients after liver transplant with 12-week sofosbuvir/daclatasvir therapy." | 7.88 | A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. ( Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM, 2018) |
| "Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection." | 7.83 | Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. ( Cerini, C; Cozzi-Lepri, A; d'Arminio Monforte, A; Giralda, M; Nasta, P; Pimenta, JM; Salmon, D; Winnock, M, 2016) |
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 7.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| " In Wistar rats, URB597 effects on alcohol-induced anxiety and on stress-, yohimbine- and cue-induced reinstatement of alcohol seeking were also evaluated." | 7.74 | Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. ( Bilbao, A; Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Defonseca, FR; Duranti, A; Piomelli, D; Tontini, A, 2008) |
| " Common adverse events included headache, asthenia, pruritus, and diarrhea." | 6.80 | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. ( Akarca, US; Hall, C; Hézode, C; Lawitz, E; Makara, M; Mobashery, N; Morillas, RM; Pilot-Matias, T; Preotescu, LL; Redman, R; Thuluvath, PJ; Varunok, P; Vilchez, RA, 2015) |
| "In clinical studies, sofosbuvir-velpatasvir has demonstrated high cure rates and favorable tolerability in patients chronically infected with chronic hepatitis C virus (HCV) of any genotype." | 5.30 | Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. ( Amrose, P; Bhatia, S; Brainard, DM; Camus, G; Chowdhury, A; Duseja, A; Goswami, B; Hyland, RH; Kabrawala, M; Kapoor, D; Koshy, A; Lu, S; Prasad, M; Saraswat, V; Sarin, SK; Shah, SR; Sood, A; Stamm, LM; Subramanian, GM, 2019) |
| "Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen." | 5.16 | Preliminary study of two antiviral agents for hepatitis C genotype 1. ( Dimitrova, DI; Eley, T; Everson, GT; Gardiner, DF; Ghalib, R; Grasela, DM; Guo, T; Lawitz, E; Lok, AS; Martorell, C; McPhee, F; Pasquinelli, C; Persson, A; Reindollar, R; Rustgi, V; Wind-Rotolo, M; Zhu, K, 2012) |
| "Hepatitis C virus could be eliminated in all patients after liver transplant with 12-week sofosbuvir/daclatasvir therapy." | 3.88 | A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. ( Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM, 2018) |
| "Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or simeprevir (SMV) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection." | 3.83 | Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. ( Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O, 2016) |
| "Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection." | 3.83 | Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. ( Cerini, C; Cozzi-Lepri, A; d'Arminio Monforte, A; Giralda, M; Nasta, P; Pimenta, JM; Salmon, D; Winnock, M, 2016) |
| "A 40-year-old man, diagnosed with decompensated liver cirrhosis because of hepatitis C virus, was on the wait list for a liver transplant when he began treatment with the direct-acting antivirals simeprevir 150 mg and sofosbuvir 400 mg." | 3.83 | First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List. ( Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K, 2016) |
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 3.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| " In Wistar rats, URB597 effects on alcohol-induced anxiety and on stress-, yohimbine- and cue-induced reinstatement of alcohol seeking were also evaluated." | 3.74 | Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. ( Bilbao, A; Braconi, S; Cannella, N; Ciccocioppo, R; Cippitelli, A; Defonseca, FR; Duranti, A; Piomelli, D; Tontini, A, 2008) |
| "Twelve weeks of the combination of direct-acting antivirals (SOF/VEL/VOX) was safe and effective in patients with relapsed hepatitis C virus infection who had previously received combination therapy with direct-acting antivirals." | 2.90 | A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). ( Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019) |
| " The combination was generally well tolerated, with an adverse event profile consistent with that observed in previous clinical trials of SMV or DCV separately." | 2.84 | Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. ( Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T, 2017) |
| " The open-label ALLY-1 study assessed the safety and efficacy of a 60-mg once-daily dosage of daclatasvir (pan-genotypic NS5A inhibitor) in combination with sofosbuvir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day for 12 weeks with a 24-week follow-up in two cohorts of patients with chronic HCV infection of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrence." | 2.82 | Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. ( Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R, 2016) |
| "Grazoprevir (GZR) is a second-generation hepatitis C virus NS3/4A protease inhibitor." | 2.82 | Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. ( Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E, 2016) |
| " Common adverse events included headache, asthenia, pruritus, and diarrhea." | 2.80 | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. ( Akarca, US; Hall, C; Hézode, C; Lawitz, E; Makara, M; Mobashery, N; Morillas, RM; Pilot-Matias, T; Preotescu, LL; Redman, R; Thuluvath, PJ; Varunok, P; Vilchez, RA, 2015) |
| " Maintenance dosing was for 9 days." | 2.76 | QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial. ( Aunes-Jansson, M; Bergfeldt, L; Berggren, A; Duris, T; Edvardsson, N; Egstrup, K; Frison, L; Gullestad, L; Johansson, S; Kochmanski, M; Kuśnierz, B; Nielsen, T; Sawicki, S, 2011) |
| "Patients suffering recurrence are known to have faster times to fibrosis and consequently higher rates of graft failure." | 2.52 | Hepatitis C management in post-transplant patients. ( Firpi, RJ; Hilgenfeldt, E, 2015) |
| "Viral recurrence occurs in all patients with detectable serum HCV RNA at the time of transplantation leading to cirrhosis in 20-30% of patients within 5 years." | 2.52 | Management of post transplant hepatitis C in the direct antiviral agents era. ( Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D, 2015) |
| "In addition, a sarcomatous change in hepatocellular carcinoma emerged 5 months after active hepatitis developed due to late hepatitis C virus relapse in this case." | 1.56 | Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. ( Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N, 2020) |
| "There were no recurrences of HCC, but there was one rejection episode and one cirrhosis decompensation episode, both 12 weeks after treatment." | 1.51 | Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center. ( Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP, 2019) |
| "Liver fibrosis was graded with the use of biopsies taken <12 months before treatment and stratified as early (0-1) or moderate to advanced (2-4) according to the Metavir score." | 1.48 | Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study. ( Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML, 2018) |
| "However, its effect on the severe recurrence and the risk of death remains controversial." | 1.46 | Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. ( Bañares, R; Casafont, F; Castellote, J; Castells, L; Cuervas-Mons, V; Espinosa, MD; Fernández, I; García-Gonzalez, M; González, A; González-Diéguez, L; Herrero, JI; Llaneras, J; Londoño, MC; Lorente, S; Molina Pérez, E; Montero Alvarez, JL; Narváez, I; Otero, A; Pascasio, JM; Pascual, S; Pons, JA; Prieto, M; Salcedo, M; Sánchez-Antolín, G; Sousa, JM; Testillano, M; Vinaixa, C, 2017) |
| "We present a case report of fulminant hepatic failure caused by genotype 2a/c HCV not only treated with LT but also complicated by severe, rapid recurrence of HCV within 6 days of transplantation." | 1.46 | Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. ( Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B, 2017) |
| " Both FAAH inhibitors: (1) blocked FAAH activity in brain and liver, increasing levels of endogenous ligands for cannabinoid and α-type peroxisome proliferator-activated (PPAR-α) receptors; (2) shifted nicotine self-administration dose-response functions in a manner consistent with reduced nicotine reward; (3) blocked reinstatement of nicotine seeking induced by reexposure to either nicotine priming or nicotine-associated cues; and (4) had no effect on cocaine or food self-administration." | 1.42 | Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. ( Armirotti, A; Auber, A; Bandiera, T; Barnes, C; Bertorelli, R; Chefer, SI; Goldberg, SR; Justinova, Z; Mascia, P; Moreno-Sanz, G; Panlilio, LV; Piomelli, D; Redhi, GH; Secci, ME; Yasar, S, 2015) |
| " Importantly, adjustments to the immunosuppressant dosage were not required." | 1.42 | Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. ( Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015) |
| "Morphine-CPP was retested 1 and 2 weeks after reactivation." | 1.40 | Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats. ( Cruz, JS; De Carvalho, CR; Pamplona, FA; Takahashi, RN, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.47) | 29.6817 |
| 2010's | 63 (92.65) | 24.3611 |
| 2020's | 4 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Merli, M | 1 |
| Rossotti, R | 1 |
| Travi, G | 1 |
| Ferla, F | 1 |
| Lauterio, A | 1 |
| Angelini Zucchetti, T | 1 |
| Alcantarini, C | 1 |
| Bargiacchi, O | 1 |
| De Carlis, L | 1 |
| Puoti, M | 1 |
| Kurokawa, K | 1 |
| Ohki, T | 1 |
| Kato, J | 1 |
| Fukumura, Y | 1 |
| Imai, M | 1 |
| Shibata, C | 1 |
| Arai, J | 1 |
| Kondo, M | 1 |
| Takagi, K | 1 |
| Kojima, K | 1 |
| Seki, M | 1 |
| Mori, M | 1 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Pisaturo, M | 1 |
| Starace, M | 2 |
| Minichini, C | 2 |
| De Pascalis, S | 2 |
| Occhiello, L | 2 |
| Fraia, AD | 1 |
| Messina, V | 1 |
| Sangiovanni, V | 1 |
| Claar, E | 1 |
| Coppola, N | 2 |
| Tholander, B | 1 |
| Koliadi, A | 1 |
| Botling, J | 1 |
| Dahlstrand, H | 1 |
| Von Heideman, A | 1 |
| Ahlström, H | 1 |
| Öberg, K | 1 |
| Ullenhag, GJ | 1 |
| Fernandes Campos, GR | 1 |
| Ward, J | 1 |
| Chen, S | 1 |
| Bittar, C | 1 |
| Vilela Rodrigues, JP | 1 |
| Martinelli, ALC | 1 |
| Souza, FF | 1 |
| Pereira, LRL | 1 |
| Rahal, P | 1 |
| Harris, M | 1 |
| Hézode, C | 6 |
| Fourati, S | 1 |
| Chevaliez, S | 1 |
| Scoazec, G | 1 |
| Soulier, A | 1 |
| Varaut, A | 1 |
| François, M | 1 |
| Ruiz, I | 1 |
| Roudot-Thoraval, F | 1 |
| Mallat, A | 1 |
| Pawlotsky, JM | 1 |
| Salcedo, M | 1 |
| Prieto, M | 2 |
| Castells, L | 3 |
| Pascasio, JM | 1 |
| Montero Alvarez, JL | 1 |
| Fernández, I | 1 |
| Sánchez-Antolín, G | 1 |
| González-Diéguez, L | 1 |
| García-Gonzalez, M | 1 |
| Otero, A | 1 |
| Lorente, S | 1 |
| Espinosa, MD | 1 |
| Testillano, M | 1 |
| González, A | 1 |
| Castellote, J | 1 |
| Casafont, F | 1 |
| Londoño, MC | 2 |
| Pons, JA | 1 |
| Molina Pérez, E | 1 |
| Cuervas-Mons, V | 1 |
| Pascual, S | 1 |
| Herrero, JI | 1 |
| Narváez, I | 1 |
| Vinaixa, C | 1 |
| Llaneras, J | 1 |
| Sousa, JM | 1 |
| Bañares, R | 1 |
| Zhou, Y | 1 |
| Schwartz, BI | 1 |
| Giza, J | 1 |
| Gross, SS | 1 |
| Lee, FS | 1 |
| Kreek, MJ | 1 |
| Ikegami, T | 2 |
| Ueda, Y | 2 |
| Akamatsu, N | 1 |
| Ishiyama, K | 1 |
| Goto, R | 1 |
| Soyama, A | 1 |
| Kuramitsu, K | 1 |
| Honda, M | 1 |
| Shinoda, M | 1 |
| Yoshizumi, T | 2 |
| Okajima, H | 1 |
| Kitagawa, Y | 1 |
| Inomata, Y | 1 |
| Ku, Y | 1 |
| Eguchi, S | 1 |
| Taketomi, A | 1 |
| Ohdan, H | 1 |
| Kokudo, N | 1 |
| Shimada, M | 1 |
| Yanaga, K | 1 |
| Furukawa, H | 1 |
| Uemoto, S | 2 |
| Maehara, Y | 2 |
| O'Brien, TR | 1 |
| Kottilil, S | 2 |
| Pfeiffer, RM | 1 |
| Teegen, EM | 1 |
| Globke, B | 1 |
| Schott, E | 2 |
| Pratschke, J | 2 |
| Eurich, D | 2 |
| Lionetti, R | 3 |
| Calvaruso, V | 1 |
| Piccolo, P | 1 |
| Mancusi, RL | 1 |
| Mazzarelli, C | 1 |
| Fagiuoli, S | 2 |
| Montalbano, M | 3 |
| Lenci, I | 2 |
| Carrai, P | 1 |
| Guaraldi, G | 2 |
| Visco-Comandini, U | 1 |
| Milana, M | 1 |
| Biolato, M | 1 |
| Loiacono, L | 2 |
| Valente, G | 1 |
| Craxì, A | 1 |
| Angelico, M | 2 |
| D'offizi, G | 2 |
| Beinhardt, S | 1 |
| Al-Zoairy, R | 1 |
| Kozbial, K | 2 |
| Stättermayer, AF | 1 |
| Maieron, A | 2 |
| Stauber, R | 1 |
| Strasser, M | 1 |
| Zoller, H | 1 |
| Graziadei, I | 2 |
| Rasoul-Rockenschaub, S | 1 |
| Trauner, M | 1 |
| Ferenci, P | 6 |
| Hofer, H | 2 |
| Uojima, H | 1 |
| Murakami, S | 1 |
| Nakatani, S | 1 |
| Hidaka, H | 1 |
| Takeuchi, A | 1 |
| Tanaka, Y | 2 |
| Inoue, T | 1 |
| Yamane, K | 1 |
| Kubota, K | 1 |
| Nakazawa, T | 1 |
| Shibuya, A | 1 |
| Koizumi, W | 1 |
| Grebely, J | 1 |
| Dalgard, O | 1 |
| Conway, B | 1 |
| Cunningham, EB | 1 |
| Bruggmann, P | 1 |
| Hajarizadeh, B | 1 |
| Amin, J | 1 |
| Bruneau, J | 1 |
| Hellard, M | 2 |
| Litwin, AH | 1 |
| Marks, P | 1 |
| Quiene, S | 1 |
| Siriragavan, S | 1 |
| Applegate, TL | 1 |
| Swan, T | 1 |
| Byrne, J | 1 |
| Lacalamita, M | 1 |
| Dunlop, A | 1 |
| Matthews, GV | 1 |
| Powis, J | 1 |
| Shaw, D | 1 |
| Thurnheer, MC | 1 |
| Weltman, M | 1 |
| Kronborg, I | 1 |
| Cooper, C | 2 |
| Feld, JJ | 2 |
| Fraser, C | 1 |
| Dillon, JF | 1 |
| Read, P | 1 |
| Gane, E | 2 |
| Dore, GJ | 1 |
| Boglione, L | 1 |
| Pinna, SM | 1 |
| Lupia, T | 1 |
| Cariti, G | 1 |
| Di Perri, G | 1 |
| Macera, M | 1 |
| Caroprese, M | 1 |
| Vitrone, M | 1 |
| Iovinella, V | 1 |
| Guerrera, B | 1 |
| Masarone, M | 1 |
| Marascio, N | 1 |
| Pavia, G | 1 |
| Romeo, I | 1 |
| Talarico, C | 1 |
| Di Salvo, S | 1 |
| Reale, M | 1 |
| Marano, V | 1 |
| Barreca, GS | 1 |
| Fabiani, F | 1 |
| Perrotti, N | 1 |
| De Siena, M | 1 |
| Giancotti, F | 1 |
| Gravina, T | 1 |
| Alcaro, S | 1 |
| Artese, A | 1 |
| Torti, C | 2 |
| Liberto, MC | 1 |
| Focà, A | 1 |
| Mucenic, M | 1 |
| Bandeira de Mello Brandao, A | 1 |
| Marroni, CA | 1 |
| Medeiros Fleck, A | 1 |
| Zanotelli, ML | 1 |
| Kiss, G | 1 |
| Meine, MH | 1 |
| Leipnitz, I | 1 |
| Soares Schlindwein, E | 1 |
| Martini, J | 1 |
| Costabeber, AM | 1 |
| Sacco, FKF | 1 |
| Cracco Cantisani, GP | 1 |
| Hayashi, K | 1 |
| Ishigami, M | 1 |
| Ishizu, Y | 1 |
| Kuzuya, T | 1 |
| Honda, T | 1 |
| Hirooka, Y | 1 |
| Toyoda, H | 1 |
| Kumada, T | 1 |
| Hattori, M | 1 |
| Katano, Y | 1 |
| Goto, H | 1 |
| Mangia, A | 2 |
| Losappio, R | 1 |
| Cenderello, G | 1 |
| Potenza, D | 1 |
| Mazzola, M | 1 |
| De Stefano, G | 1 |
| Terreni, N | 1 |
| Copetti, M | 1 |
| Minerva, N | 1 |
| Piazzola, V | 1 |
| Bacca, D | 1 |
| Palmieri, V | 1 |
| Sogari, F | 1 |
| Santoro, R | 1 |
| Harada, N | 1 |
| Itoh, S | 1 |
| Furusho, N | 1 |
| Kato, M | 1 |
| Shimoda, S | 1 |
| Fukuhara, T | 1 |
| Soejima, Y | 1 |
| Jung, BH | 1 |
| Park, JI | 1 |
| Lee, SG | 1 |
| Khan, AJ | 1 |
| Saraswat, VA | 1 |
| Ranjan, P | 1 |
| Parmar, D | 1 |
| Negi, TS | 1 |
| Mohindra, S | 1 |
| Sood, A | 1 |
| Duseja, A | 1 |
| Kabrawala, M | 1 |
| Amrose, P | 1 |
| Goswami, B | 1 |
| Chowdhury, A | 1 |
| Sarin, SK | 1 |
| Koshy, A | 1 |
| Hyland, RH | 1 |
| Lu, S | 1 |
| Camus, G | 1 |
| Stamm, LM | 1 |
| Brainard, DM | 3 |
| Subramanian, GM | 1 |
| Prasad, M | 1 |
| Bhatia, S | 1 |
| Shah, SR | 1 |
| Kapoor, D | 1 |
| Saraswat, V | 1 |
| Li, H | 1 |
| Tan, JL | 1 |
| Li, JR | 1 |
| Liu, NN | 1 |
| Chen, JH | 1 |
| Lv, XQ | 1 |
| Zou, LL | 1 |
| Dong, B | 1 |
| Peng, ZG | 1 |
| Jiang, JD | 1 |
| Wilson, E | 1 |
| Covert, E | 1 |
| Hoffmann, J | 1 |
| Comstock, E | 1 |
| Emmanuel, B | 1 |
| Tang, L | 1 |
| Husson, J | 1 |
| Chua, J | 1 |
| Price, A | 1 |
| Mathur, P | 1 |
| Rosenthal, E | 1 |
| Kattakuzhy, S | 1 |
| Masur, H | 1 |
| Papaluca, T | 1 |
| Sinclair, M | 1 |
| Gow, P | 1 |
| Pianko, S | 1 |
| Sievert, W | 1 |
| Arachchi, N | 1 |
| Cameron, K | 1 |
| Bowden, S | 1 |
| O'Keefe, J | 1 |
| Doyle, J | 1 |
| Stoove, M | 1 |
| Iser, D | 1 |
| Thompson, A | 1 |
| Zanaga, LP | 1 |
| Santos, AG | 1 |
| Ataíde, EC | 1 |
| Boin, IFSF | 1 |
| Stucchi, RSB | 1 |
| Fontana, RJ | 4 |
| Hughes, EA | 3 |
| Bifano, M | 2 |
| Appelman, H | 2 |
| Dimitrova, D | 2 |
| Hindes, R | 2 |
| Symonds, WT | 1 |
| De Carvalho, CR | 1 |
| Pamplona, FA | 1 |
| Cruz, JS | 1 |
| Takahashi, RN | 1 |
| Poordad, F | 3 |
| Trinh, R | 1 |
| Kowdley, KV | 1 |
| Zeuzem, S | 5 |
| Agarwal, K | 3 |
| Shiffman, ML | 1 |
| Wedemeyer, H | 1 |
| Berg, T | 2 |
| Yoshida, EM | 1 |
| Forns, X | 2 |
| Lovell, SS | 1 |
| Da Silva-Tillmann, B | 1 |
| Collins, CA | 1 |
| Campbell, AL | 1 |
| Podsadecki, T | 3 |
| Bernstein, B | 1 |
| Bernstein, D | 1 |
| Lalezari, J | 1 |
| Cohen, D | 2 |
| Luo, Y | 1 |
| Tam, E | 1 |
| Marinho, RT | 1 |
| Tsai, N | 1 |
| Nyberg, A | 1 |
| Box, TD | 1 |
| Younes, Z | 2 |
| Enayati, P | 1 |
| Green, S | 1 |
| Baruch, Y | 2 |
| Bhandari, BR | 1 |
| Caruntu, FA | 1 |
| Sepe, T | 1 |
| Chulanov, V | 1 |
| Janczewska, E | 1 |
| Rizzardini, G | 1 |
| Gervain, J | 1 |
| Planas, R | 2 |
| Moreno, C | 3 |
| Hassanein, T | 1 |
| Xie, W | 2 |
| King, M | 1 |
| Reddy, KR | 2 |
| Pellicelli, AM | 2 |
| Durand, C | 1 |
| Knop, V | 2 |
| Telese, A | 1 |
| Andreoli, A | 1 |
| Hilgenfeldt, E | 1 |
| Firpi, RJ | 1 |
| Chauvet, C | 1 |
| Nicolas, C | 1 |
| Thiriet, N | 1 |
| Lardeux, MV | 1 |
| Duranti, A | 2 |
| Solinas, M | 1 |
| Justinova, Z | 1 |
| Panlilio, LV | 1 |
| Moreno-Sanz, G | 1 |
| Redhi, GH | 1 |
| Auber, A | 1 |
| Secci, ME | 1 |
| Mascia, P | 1 |
| Bandiera, T | 1 |
| Armirotti, A | 1 |
| Bertorelli, R | 1 |
| Chefer, SI | 1 |
| Barnes, C | 1 |
| Yasar, S | 1 |
| Piomelli, D | 2 |
| Goldberg, SR | 1 |
| Coilly, A | 2 |
| Roche, B | 1 |
| Duclos-Vallée, JC | 2 |
| Samuel, D | 2 |
| Herzer, K | 4 |
| Papadopoulos-Köhn, A | 1 |
| Walker, A | 1 |
| Achterfeld, A | 1 |
| Paul, A | 1 |
| Canbay, A | 1 |
| Timm, J | 1 |
| Gerken, G | 1 |
| Kalafateli, M | 1 |
| Dusheiko, G | 1 |
| Manousou, P | 1 |
| Lawitz, E | 2 |
| Makara, M | 1 |
| Akarca, US | 1 |
| Thuluvath, PJ | 1 |
| Preotescu, LL | 1 |
| Varunok, P | 1 |
| Morillas, RM | 1 |
| Hall, C | 1 |
| Mobashery, N | 1 |
| Redman, R | 1 |
| Pilot-Matias, T | 1 |
| Vilchez, RA | 1 |
| Sollima, S | 1 |
| Milazzo, L | 1 |
| Torre, A | 1 |
| Calvi, E | 1 |
| Regalia, E | 1 |
| Antinori, S | 1 |
| Jacobson, IM | 1 |
| Asselah, T | 1 |
| Ruane, PJ | 1 |
| Gruener, N | 1 |
| Abergel, A | 2 |
| Lai, CL | 1 |
| Chan, HL | 1 |
| Mazzotta, F | 1 |
| Yoshida, E | 1 |
| Shafran, SD | 1 |
| Towner, WJ | 1 |
| Tran, TT | 1 |
| McNally, J | 1 |
| Osinusi, A | 1 |
| Svarovskaia, E | 1 |
| Zhu, Y | 1 |
| McHutchison, JG | 2 |
| Saab, S | 1 |
| Gonzalez, YS | 1 |
| Huber, C | 1 |
| Wang, A | 1 |
| Juday, T | 1 |
| Schiff, ER | 1 |
| Vierling, JM | 1 |
| Landis, C | 1 |
| Yang, R | 1 |
| McPhee, F | 2 |
| Noviello, S | 1 |
| Swenson, ES | 1 |
| Brown, RS | 1 |
| Moreno-Zamora, A | 1 |
| Joshi, S | 1 |
| Chacko, KR | 1 |
| Stauber, RE | 2 |
| Jafri, SM | 1 |
| Durand, CM | 1 |
| Bahirwani, R | 1 |
| Weiland, O | 2 |
| Mubarak, A | 1 |
| ElSharkawy, AM | 1 |
| Stadler, B | 1 |
| Berg, C | 1 |
| Stenmark, S | 1 |
| Vekeman, F | 1 |
| Ionescu-Ittu, R | 1 |
| Emond, B | 1 |
| Campos-Varela, I | 1 |
| Moreno, A | 1 |
| Morbey, A | 1 |
| Hasson, H | 1 |
| Bhamidimarri, KR | 1 |
| Grewal, P | 1 |
| Baños, I | 1 |
| Bellot, P | 1 |
| Terrault, NA | 1 |
| Nasta, P | 1 |
| Salmon, D | 1 |
| d'Arminio Monforte, A | 1 |
| Pimenta, JM | 1 |
| Cerini, C | 1 |
| Giralda, M | 1 |
| Winnock, M | 1 |
| Cozzi-Lepri, A | 1 |
| Stern, R | 1 |
| Hametner, S | 1 |
| Ramona, AZ | 1 |
| Moser, S | 1 |
| Karpi, A | 1 |
| Laferl, H | 1 |
| Zoller, HM | 1 |
| Vogel, W | 1 |
| Gschwantler, M | 1 |
| Freissmuth, C | 1 |
| Ben Ari, Z | 1 |
| Mollison, L | 1 |
| Zuckerman, E | 1 |
| Bruck, R | 1 |
| Howe, AY | 1 |
| Wahl, J | 1 |
| Bhanja, S | 1 |
| Hwang, P | 1 |
| Zhao, Y | 3 |
| Robertson, MN | 1 |
| Figueiredo, CP | 1 |
| Bang, H | 1 |
| Cobra, JF | 1 |
| Englbrecht, M | 1 |
| Hueber, AJ | 1 |
| Haschka, J | 1 |
| Manger, B | 1 |
| Kleyer, A | 1 |
| Reiser, M | 1 |
| Finzel, S | 1 |
| Tony, HP | 1 |
| Kleinert, S | 1 |
| Wendler, J | 1 |
| Schuch, F | 1 |
| Ronneberger, M | 1 |
| Feuchtenberger, M | 1 |
| Fleck, M | 1 |
| Manger, K | 1 |
| Ochs, W | 1 |
| Schmitt-Haendle, M | 1 |
| Lorenz, HM | 1 |
| Nuesslein, H | 1 |
| Alten, R | 1 |
| Henes, J | 1 |
| Krueger, K | 1 |
| Rech, J | 1 |
| Schett, G | 1 |
| Santagostino, E | 1 |
| Pol, S | 1 |
| Olveira, A | 1 |
| Reesink, HW | 1 |
| van Erpecum, K | 1 |
| Bogomolov, P | 1 |
| Xu, D | 1 |
| Critelli, L | 1 |
| Srinivasan, S | 1 |
| Cooney, E | 1 |
| Dumortier, J | 1 |
| Leroy, V | 2 |
| Duvoux, C | 1 |
| de Ledinghen, V | 2 |
| Francoz, C | 1 |
| Houssel-Debry, P | 1 |
| Radenne, S | 1 |
| d'Alteroche, L | 2 |
| Fougerou-Leurent, C | 1 |
| Canva, V | 1 |
| di Martino, V | 2 |
| Conti, F | 1 |
| Kamar, N | 1 |
| Lebray, P | 2 |
| Tran, A | 1 |
| Besch, C | 1 |
| Diallo, A | 1 |
| Rohel, A | 1 |
| Rossignol, E | 1 |
| Botta-Fridlund, D | 2 |
| Pageaux, GP | 1 |
| Raschzok, N | 1 |
| Reutzel-Selke, A | 1 |
| Damrah, I | 1 |
| Gül-Klein, S | 1 |
| Strücker, B | 1 |
| Sauer, IM | 1 |
| Stockmann, M | 1 |
| Yesmembetov, K | 1 |
| Ashimkhanova, A | 1 |
| Kaliaskarova, K | 1 |
| Elmasry, S | 1 |
| Wadhwa, S | 1 |
| Bang, BR | 1 |
| Cook, L | 1 |
| Chopra, S | 1 |
| Kanel, G | 1 |
| Kim, B | 1 |
| Harper, T | 1 |
| Feng, Z | 1 |
| Jerome, KR | 1 |
| Kahn, JA | 1 |
| Saito, T | 1 |
| Welzel, TM | 1 |
| Spengler, U | 1 |
| Hinrichsen, H | 1 |
| Klinker, H | 1 |
| Peck-Radosavljevic, M | 1 |
| Inderson, A | 1 |
| Jimenez-Exposito, MJ | 1 |
| Almasio, PL | 1 |
| Bourgeois, S | 1 |
| Buggisch, P | 1 |
| Brown, A | 1 |
| Diago, M | 1 |
| Horsmans, Y | 1 |
| Serfaty, L | 1 |
| Szalay, F | 1 |
| Gaeta, GB | 1 |
| Schlag, M | 1 |
| Lonjon-Domanec, I | 1 |
| Omoruyi, E | 1 |
| DeMasi, R | 1 |
| Zoulim, F | 1 |
| Boyer, N | 1 |
| Larrey, D | 1 |
| Silvain, C | 1 |
| Fontaine, H | 1 |
| Bourliere, M | 1 |
| Hubert-Fouchard, I | 1 |
| Guyader, D | 1 |
| Rosa, I | 1 |
| Nguyen-Khac, E | 1 |
| Fedchuk, L | 1 |
| Akremi, R | 1 |
| Bennai, Y | 1 |
| Filipovics, A | 1 |
| Bronowicki, JP | 1 |
| Castedal, M | 1 |
| Segenmark, M | 1 |
| Cederberg, S | 1 |
| Skoglund, C | 1 |
| Tracy, B | 1 |
| Shrestha, R | 1 |
| Stein, L | 1 |
| Bhasin, D | 1 |
| Pollinger, H | 1 |
| Rubin, RA | 1 |
| Berenguer, M | 1 |
| Sterneck, M | 1 |
| Donato, MF | 1 |
| Andreone, P | 1 |
| Cieciura, T | 1 |
| Durlik, M | 1 |
| Calleja, JL | 1 |
| Mariño, Z | 1 |
| Shukla, U | 1 |
| Verbinnen, T | 1 |
| Lenz, O | 1 |
| Ouwerkerk-Mahadevan, S | 1 |
| Peeters, M | 1 |
| Janssen, K | 1 |
| Kalmeijer, R | 1 |
| Jessner, W | 1 |
| Egstrup, K | 1 |
| Bergfeldt, L | 1 |
| Duris, T | 1 |
| Gullestad, L | 1 |
| Kochmanski, M | 1 |
| Kuśnierz, B | 1 |
| Nielsen, T | 1 |
| Sawicki, S | 1 |
| Aunes-Jansson, M | 1 |
| Edvardsson, N | 1 |
| Frison, L | 1 |
| Johansson, S | 1 |
| Berggren, A | 1 |
| Lok, AS | 1 |
| Gardiner, DF | 1 |
| Martorell, C | 1 |
| Everson, GT | 1 |
| Ghalib, R | 1 |
| Reindollar, R | 1 |
| Rustgi, V | 1 |
| Wind-Rotolo, M | 1 |
| Persson, A | 1 |
| Zhu, K | 1 |
| Dimitrova, DI | 1 |
| Eley, T | 1 |
| Guo, T | 1 |
| Grasela, DM | 1 |
| Pasquinelli, C | 1 |
| Cippitelli, A | 1 |
| Cannella, N | 1 |
| Braconi, S | 1 |
| Tontini, A | 1 |
| Bilbao, A | 1 |
| Defonseca, FR | 1 |
| Ciccocioppo, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use[NCT02336139] | Phase 2 | 103 participants (Actual) | Interventional | 2016-03-16 | Completed | ||
| The Puglia HCV Micro-elimination in People With Substance Use Disorders[NCT03923595] | 231 participants (Actual) | Observational | 2019-07-30 | Completed | |||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study[NCT02639585] | Phase 4 | 32 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney[NCT03296930] | Phase 4 | 100 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | ||
| A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis [NCT01767116] | Phase 3 | 419 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis [NCT01833533] | Phase 3 | 305 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study[NCT02702739] | Phase 4 | 270 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)[NCT01685203] | Phase 2 | 316 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir in Pregnant Women With Chronic Hepatitis C Virus Infection[NCT04382404] | Phase 1 | 11 participants (Actual) | Interventional | 2020-10-22 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV[NCT02201940] | Phase 3 | 741 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient[NCT03801707] | Phase 2/Phase 3 | 54 participants (Actual) | Interventional | 2019-03-22 | Completed | ||
| Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine[NCT04038320] | 868 participants (Actual) | Observational | 2018-03-26 | Completed | |||
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C: Multi-center, Prospective, Observational Real-world Study in EASTERN China[NCT04952207] | 300 participants (Anticipated) | Observational [Patient Registry] | 2019-03-06 | Recruiting | |||
| A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection[NCT01716156] | Phase 2 | 26 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects[NCT02268864] | Phase 2 | 106 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection [NCT01938625] | Phase 2 | 35 participants (Actual) | Interventional | 2013-12-12 | Completed | ||
| A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placeb[NCT00643448] | Phase 2 | 65 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV[NCT02124044] | Phase 2 | 30 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1[NCT01012895] | Phase 2 | 215 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01767116)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 51.2 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.4 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b infection treated with telaprevir and peginterferon/RBV (pegIFN)." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100.0 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary endpoint was the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b treated with telaprevir and pegIFN/RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of particpants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01767116)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0.5 | 0 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01833533)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 42.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.9 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and peginterferon(pegIFN)/RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and pegIFN/RBV; and the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 5.2 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01833533)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 2.9 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01685203)
Timeframe: Baseline (Day 1), Day 3, and Treatment Weeks 1, 2 ,3 ,4, 6, 8, 10, and 12 for all participants and Treatment Weeks 16, 20 and 24 for Groups 7 and 8
| Intervention | Percentage of participants (Number) |
|---|---|
| Group 1 | 2.3 |
| Group 2 | 0 |
| Group 3 | 2.5 |
| Group 4 | 0 |
| Group 6 | 0 |
| Group 7 | 0 |
| Group 8 | 0 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01685203)
Timeframe: Within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| Group 1 | 4.8 |
| Group 2 | 0 |
| Group 3 | 7.7 |
| Group 4 | 0 |
| Group 6 | 0 |
| Group 7 | 0 |
| Group 8 | 1.9 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| Group 1 | 90.9 |
| Group 2 | 95.2 |
| Group 3 | 90.0 |
| Group 4 | 100 |
| Group 6 | 100 |
| Group 7 | 97.9 |
| Group 8 | 98.1 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [
Timeframe: 24 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| Group 1 | 86.4 |
| Group 2 | 92.9 |
| Group 3 | 90.0 |
| Group 4 | 100.0 |
| Group 6 | 100.0 |
| Group 7 | 97.9 |
| Group 8 | 98.1 |
Treatment-emergent adverse events were defined as any event that began or worsened in severity after initiation of study drug through 30 days after the last dose of study drug. (NCT01685203)
Timeframe: From the start of study drug administration until 30 days after the last dose,16 weeks for Groups 1, 2, 3, 4, and 6, and 28 weeks for Groups 7 and 8.
| Intervention | Percentage of participants (Number) |
|---|---|
| Group 1 | 77.3 |
| Group 2 | 73.8 |
| Group 3 | 80.0 |
| Group 4 | 88.1 |
| Group 6 | 85.7 |
| Group 7 | 85.1 |
| Group 8 | 71.2 |
(NCT02201940)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 0.2 |
| Placebo | 1.7 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment. (NCT02201940)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 99.0 |
| Placebo | 0 |
"Virologic failure was defined as:~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit." (NCT02201940)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 0.3 |
| Placebo | 100 |
(NCT02201940)
Timeframe: Baseline; Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | log10 IU/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Wk 1 (SOF/VEL: N= 617; Placebo: N= 114) | Change at Wk 2 (SOF/VEL: N= 622; Placebo: N= 116) | Change at Wk 4 (SOF/VEL: N= 617; Placebo: N= 114) | Change at Wk 6 (SOF/VEL: N= 623; Placebo: N= 115) | Change at Wk 8 (SOF/VEL: N= 622; Placebo: N= 113) | Change at Wk 10 (SOF/VEL: N= 622; Placebo: N= 112) | Change at Wk 12 (SOF/VEL: N= 622; Placebo: N= 111) | |
| Placebo | -0.05 | 0.01 | -0.01 | 0.07 | 0.05 | 0.05 | -0.06 |
| SOF/VEL | -4.29 | -4.82 | -5.08 | -5.11 | -5.11 | -5.12 | -5.12 |
(NCT02201940)
Timeframe: Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (SOF/VEL: N = 624; Placebo: N = 116) | Week 2 (SOF/VEL: N = 624; Placebo: N = 116) | Week 4 (SOF/VEL: N = 623; Placebo: N = 116) | Week 6 (SOF/VEL: N = 623; Placebo: N = 115) | Week 8 (SOF/VEL: N = 622; Placebo: N = 114) | Week 10 (SOF/VEL: N = 622; Placebo: N = 114) | Week 12 (SOF/VEL: N = 622; Placebo: N = 113) | |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SOF/VEL | 18.8 | 56.9 | 90.5 | 98.9 | 99.7 | 100.0 | 100.0 |
SVR4 and SVR 24 were defined as HCV RNA < LLOQ at 4 and 24 weeks after stopping study treatment, respectively. (NCT02201940)
Timeframe: Posttreatment Weeks 4 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| SVR4 | SVR24 | |
| Placebo | 0 | 0 |
| SOF/VEL | 99.2 | 99.0 |
Proportion of patients with undetectable hepatitis C virus (HCV) polymerase chain reaction (PCR) at 12 weeks after completion of HCV treatment was to test the efficacy of the treatment. (NCT03801707)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group | 28 |
Estimated glomerular filtration rate (eGFR) at 6 and 12 months post-transplant was to test the safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | ml/min/1.73m^2 (Median) | |
|---|---|---|
| eGFR at 6 months | eGFR at 12 months | |
| Intervention Group | 54 | 46 |
Graft survival at 6 and 12 months measuring safety of utilizing HepC positive kidneys. (NCT03801707)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months graft survival | 12 months graft survival | |
| Intervention Group | 30 | 30 |
Patient's survival at 6 and 12 months measuring safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months patient survival | 12 months patient survival | |
| Intervention Group | 30 | 30 |
SVR12 was defined as HCV RNA <25 IU/mL 12 weeks after the end of all study therapy. HCV RNA was measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay, which has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. (NCT01716156)
Timeframe: Up to Week 36
| Intervention | Percentage of participants (Number) |
|---|---|
| Grazoprevir 100 mg + RBV 12 Weeks | 58.3 |
| Grazoprevir 100 mg + RBV 24 Weeks | 90.0 |
HCV RNA was measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay, which has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. SVR24 was defined as HCV RNA <25 IU/mL 24 weeks after the end of all study therapy. (NCT01716156)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Grazoprevir 100 mg + RBV 12 Weeks | 62.5 |
| Grazoprevir 100 mg + RBV 12 Weeks Extended | 50.0 |
| Grazoprevir 100 mg + RBV 24 Weeks | 80.0 |
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data are presented according to actual treatment duration (12 weeks or 24 weeks) regardless of participants' initial arm assignment. (NCT01716156)
Timeframe: Up to 24 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Grazoprevir 100 mg + RBV: up to 12 Weeks | 0 |
| Grazoprevir 100 mg + RBV: Beyond 12 Weeks | 0 |
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. Data are presented according to actual treatment duration (12 weeks or 24 weeks) regardless of participants' initial arm assignment. (NCT01716156)
Timeframe: Fourteen days following last dose of study drug (up to 26 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Grazoprevir 100 mg + RBV: up to 12 Weeks | 72.7 |
| Grazoprevir 100 mg + RBV: Beyond 12 Weeks | 86.7 |
HCV RNA was measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay, which has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. SVR4 was defined as HCV RNA <25 IU/mL 4 weeks after the end of all study therapy. (NCT01716156)
Timeframe: Up to Week 28
| Intervention | Percentage of participants (Number) |
|---|---|
| Grazoprevir 100 mg + RBV 12 Weeks | 87.5 |
| Grazoprevir 100 mg + RBV 12 Weeks Extended | 75.0 |
| Grazoprevir 100 mg + RBV 24 Weeks | 90.9 |
The mean time (in days) to first achievement of undetectable HCV RNA was assessed using Kaplan-Meier plot and summary statistics. HCV RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay on blood samples drawn from each participant at Week 2, Week 4, Week 12, and at end of treatment. The assay has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. Undetectable HCV RNA was defined as below the limit of detection of 9.3 IU/mL. (NCT01716156)
Timeframe: Up to Week 24
| Intervention | Days (Mean) |
|---|---|
| Grazoprevir 100 mg + RBV HCV GT1a | 27.1 |
| Grazoprevir 100 mg + RBV HCV GT1non-a | 19.7 |
HCV RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay on blood samples drawn from each participant at Week 2, Week 4, Week 12, and at end of treatment (End of Treatment Response). The assay has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. Undetectable HCV RNA was defined as below the limit of detection of 9.3 IU/mL. (NCT01716156)
Timeframe: From Week 2 through end of treatment (up to 24 weeks)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4; Grazoprevir 100 mg + RBV 24 Weeks, n=11 | Week 12; Grazoprevir 100 mg + RBV 24 Weeks, n=11 | End of all therapy | |
| Grazoprevir 100 mg + RBV 12 Weeks | 100.0 | 100.0 | 100.0 | 100.0 |
| Grazoprevir 100 mg + RBV 12 Weeks Extended | 75.0 | 100.0 | 75.0 | 75.0 |
| Grazoprevir 100 mg + RBV 24 Weeks | 100.0 | 100.0 | 90.9 | 91.7 |
HCV RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test, v2.0® assay on blood samples drawn from each participant at Week 2, Week 4, Week 12, and at end of treatment (End of Treatment Response). The assay has a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL. Undetectable HCV RNA was defined as below the limit of detection of 9.3 IU/mL. (NCT01716156)
Timeframe: From Week 2 through end of treatment (up to 24 weeks)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4; Grazoprevir 100 mg + RBV 24 Weeks, n=11 | Week 12; Grazoprevir 100 mg + RBV 24 Weeks, n=11 | End of all therapy | |
| Grazoprevir 100 mg + RBV 12 Weeks | 50.0 | 100.0 | 100.0 | 100.0 |
| Grazoprevir 100 mg + RBV 12 Weeks Extended | 0.0 | 0.0 | 75.0 | 75.0 |
| Grazoprevir 100 mg + RBV 24 Weeks | 41.7 | 81.8 | 81.8 | 91.7 |
Participants were considered to have had viral breakthrough if they had a confirmed greater than (>) 1.0 log10 international units/milliliter (IU/mL) increase in HCV RNA from nadir OR confirmed HCV RNA >100 IU/mL while previously having achieved HCV RNA
Timeframe: Up to Week 24
| Intervention | participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 4 |
| 12 Weeks Post Amendment | 0 |
| 24 Weeks Extension | 3 |
Participants were considered to have had viral relapse if they did not achieve SVR12 and met the following conditions: had HCV RNA
Timeframe: Up to Week 24 after actual EOT
| Intervention | participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 0 |
| 12 Weeks Post Amendment | 0 |
| 24 Weeks Extension | 1 |
Participants were considered on-treatment failures if they did not achieve SVR12 and had (confirmed) detectable HCV RNA, ie,
Timeframe: Up to Week 24 after actual EOT
| Intervention | percentage of participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 29.4 |
| 12 Weeks Post Amendment | 0.0 |
| 24 Weeks Extension | 4.7 |
Participants were considered to have reached SVR12, if 12 weeks after the actual end of treatment (EOT), hepatitis C virus (HCV) ribonucleic acid (RNA) was less than lower limit of quantification (
Timeframe: At 12 weeks after end of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 70.6 |
| 12 Weeks Post Amendment | 100 |
| 24 Weeks Extension | 93.8 |
Participants were considered to have reached SVR4, if 4 weeks after the actual EOT, HCV RNA was
Timeframe: At 4 weeks after actual EOT
| Intervention | percentage of participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 70.6 |
| 12 Weeks Post Amendment | 100 |
| 24 Weeks Extension | 93.8 |
Participants were considered to have reached SVR24, if 24 weeks after the actual EOT, HCV RNA was
Timeframe: At 24 weeks after actual EOT
| Intervention | percentage of participants (Number) |
|---|---|
| 12 Weeks Prior Amendment | 70.6 |
| 12 Weeks Post Amendment | 100 |
| 24 Weeks Extension | 93.8 |
On-treatment failure is defined as participants who did not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of treatment. This was to include participants with: 1) Viral breakthrough, defined as a confirmed increase of greater than (>)1 log10 in HCV RNA from nadir, or confirmed HCV RNA of >100 IU/mL in participants whose HCV RNA had previously been
Timeframe: Up to Week 24 after actual EOT (week 24)
| Intervention | participants (Number) |
|---|---|
| Cyclosporine | 0 |
| Tacrolimus | 3 |
Viral breakthrough is defined as a confirmed increase of >1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of >100 IU/mL in participants whose HCV RNA levels had previously been below the limit of quantification (<25 IU/mL detectable) or undetectable (<25 IU/mL undetectable) while on study treatment. (NCT01938625)
Timeframe: Up to week 24
| Intervention | participants (Number) |
|---|---|
| Cyclosporine | 0 |
| Tacrolimus | 3 |
Participants who did not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (>=) LLOQ during follow-up. (NCT01938625)
Timeframe: Up to Week 24 after actual EOT (week 24)
| Intervention | participants (Number) |
|---|---|
| Cyclosporine | 0 |
| Tacrolimus | 0 |
Percentage of participants with HCV RNA (<) 100 IU/mL at week 4 were reported. (NCT01938625)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Cyclosporine | 100 |
| Tacrolimus | 100 |
Participants were considered to have achieved SVR12 if hepatitis C virus ribonucleic acid (HCV RNA) levels were less than (<) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after the end of treatment. (NCT01938625)
Timeframe: Week 36
| Intervention | percentage of participants (Number) |
|---|---|
| Cyclosporine | 100 |
| Tacrolimus | 88 |
Participants were considered to have achieved SVR 24 if hepatitis C virus ribonucleic acid (HCV RNA) levels were (<) 25 IU/mL detectable or undetectable at 24 weeks after the end of treatment. (NCT01938625)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cyclosporine | 100 |
| Tacrolimus | 88 |
Participants were considered to have achieved SVR4 if HCV RNA levels were (<) 25 IU/mL detectable or undetectable at 4 weeks after the end of treatment. (NCT01938625)
Timeframe: Week 28
| Intervention | percentage of participants (Number) |
|---|---|
| Cyclosporine | 100 |
| Tacrolimus | 88 |
Percentage of participants with detectable and undetectable HCV RNA (<) 25 IU/mL during treatment at Weeks 2,4, 12, and 24 were reported. (NCT01938625)
Timeframe: Weeks 2, 4, 12, and 24
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2: <25 IU/mL detectable | Week 2: <25 IU/mL undetectable | Week 4: <25 IU/mL detectable | Week 4: <25 IU/mL undetectable | Week 12: <25 IU/mL detectable | Week 12: <25 IU/mL undetectable | Week 24: <25 IU/mL detectable | Week 24: <25 IU/mL undetectable | |
| Cyclosporine | 30 | 10 | 30 | 70 | 0 | 100 | 0 | 100 |
| Tacrolimus | 36 | 12 | 24 | 68 | 0 | 96 | 0 | 100 |
Number of patients who had at least one AE according to the definition in the study protocol (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | Participants (Number) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 22 |
| Placebo | 13 |
Percentage of twice daily TTM recordings (individual compliance) transmitted and available for analysis (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | Percentage of recordings analysed (Mean) |
|---|---|
| AZD1305 Group A | 97.4 |
| AZD1305 Group B | 96.4 |
| Placebo | 98.3 |
Population PK model parameter estimates derived from plasma concentrations of AZD1305 (NCT00643448)
Timeframe: During treatment days 1-10
| Intervention | μmol/L (Mean) |
|---|---|
| AZD1305 Group A | 0.41 |
| AZD1305 Group B | 0.45 |
Maximum of all QTcF values obtained for any given patient from randomisation until the intended end of the study drug period, day 10. (NCT00643448)
Timeframe: During treatment days 2-10
| Intervention | ms (Mean) |
|---|---|
| AZD1305 Group A and AZD1305 Group B | 461 |
| Placebo | 427 |
The primary outcome was the percentage of patients with sustained viral response measured 12 weeks after the stop of treatment. The viral response was assessed by serum HCV RNA concentrations lower than 43 IU/mL - the lower limit of quantification. (NCT02124044)
Timeframe: 12 weeks after stop of treatment
| Intervention | Percentage of subjects (Number) |
|---|---|
| HIV/HCV GT-1a/1b, 12 Wks ASV/DCV With BMS-791325 | 90 |
| HIV/HCV GT-1b, 24 Wks ASV/DCV | 80 |
2 reviews available for carbamates and Recrudescence
| Article | Year |
|---|---|
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Het | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Li | 2015 |
19 trials available for carbamates and Recrudescence
| Article | Year |
|---|---|
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatiti | 2017 |
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Packag | 2018 |
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Topics: Adult; Aged; Carbamates; Drug Combinations; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatiti | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; | 2019 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; | 2019 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug The | 2014 |
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Administration Schedule; D | 2014 |
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Carbamates; Carrier Proteins; Cyclopropanes; | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations | 2015 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hep | 2016 |
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Re | 2016 |
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genoty | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hep | 2016 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Comb | 2016 |
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Gen | 2017 |
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype | 2017 |
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Azabicyclo Compounds; Carbamates; Delayed-Action | 2011 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Geno | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Geno | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Geno | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Geno | 2012 |
47 other studies available for carbamates and Recrudescence
| Article | Year |
|---|---|
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Res | 2019 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis | 2020 |
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Comb | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystade | 2020 |
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug | 2021 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; H | 2017 |
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazole | 2017 |
Blockade of alcohol escalation and "relapse" drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholism; Amidohydrolases; Animals; Benzamides; Carbamates; Endocannabinoids; Et | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studie | 2017 |
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hep | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy | 2018 |
Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype | 2018 |
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Exp | 2018 |
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropane | 2018 |
Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Male; Models, Molecular; | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Follow-Up Studies; Genotype; H | 2018 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic | 2018 |
Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Topics: Aged; Antiviral Agents; Carbamates; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; F | 2018 |
Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; I | 2018 |
Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Case-Control Studies; Female; Genetic Predisposition to D | 2019 |
A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.
Topics: Antiviral Agents; Carbamates; Cell Death; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combinatio | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; | 2019 |
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Topics: Carbamates; Cholestasis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Stud | 2013 |
Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats.
Topics: Amidohydrolases; Animals; Benzamides; Benzoxazines; Carbamates; Conditioning, Psychological; Cues; E | 2014 |
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Vira | 2015 |
Chronic stimulation of the tone of endogenous anandamide reduces cue- and stress-induced relapse in rats.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Cocaine; Cocaine-Related Disord | 2014 |
Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse.
Topics: Animals; Benzamides; Biphenyl Compounds; Brain; Carbamates; Cues; Dopamine; Dose-Response Relationsh | 2015 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepati | 2015 |
Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Intera | 2016 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, C | 2016 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug | 2016 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Gen | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease | 2016 |
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cause of Death; CD4 Lymphocyte Count; Coin | 2016 |
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fa | 2016 |
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
Topics: Acetates; Acetylation; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Carbamates; Citr | 2017 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2016 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Dru | 2017 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Live | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage L | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genoty | 2017 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy | 2012 |
Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.
Topics: Adrenergic alpha-Antagonists; Alcohol Drinking; Alcoholism; Amidohydrolases; Animals; Anxiety; Arach | 2008 |